Snelix, an Italian biotech startup that turns snail mucus into bio‑active peptides for cosmeceutical and nutraceutical applications, raised more than €1 million through three public grant schemes, minimizing equity dilution while advancing its product pipeline.
Aiom is urging US biotech company Revolution Medicines to launch a compassionate‑use program for daraxonrasib, a targeted therapy that has doubled survival in a pancreatic cancer trial. While the drug received FDA approval in the United States, no similar early‑access program exists in Europe, and Revolution Medicines has not submitted a registration dossier to the European Medicines Agency. Aiom and Italian oncologists argue the drug should be provided free of charge to Italian patients pending approval, citing ethical concerns over high import costs.
Swedish spatial‑biology startup Cubase Bio teamed up with Austrian organoid company HeartBeat.bio, receiving about €1 million in Eurostars funding to create the FACTS‑3D project, which combines Cubase Bio’s 3D spatial transcriptomics with HeartBeat.bio’s cardiac organoids for high‑throughput drug discovery targeting myocardial fibrosis.
Amanda Mattsson and co‑founder Lova Svensson started Period Pack as a school project and grew it into a company with million‑euro profits operating across Europe. Mattsson is now leaving her role as CEO and selling her shares in the business.
Spanish biotech CONNECTA Therapeutics raised €3.1 million, led by Clave Capital, to fund the next phase of clinical trials for a novel treatment targeting Fragile X syndrome, a neurodevelopmental disorder with no approved therapies.
French medtech startup Implicity secured a €35 million financing round led by IRIS and Five Arrows to enhance its platform that aggregates cardiac device data and enables predictive cardiology, supporting its growth in the U.S. market.
BIOSINTEX SRL, a Romanian manufacturer of high‑performance surgical sutures, together with technology partner TRICUBIQ SOLUTIONS SRL, has completed a 16‑month project worth 18.07 million lei that automates key production processes through robotics, AI and digital tools. The project, financed by the EU‑backed PNRR, enhances BIOSINTEX’s production capacity, quality control and international market position.
Portuguese digital‑health startup Hope Care raised €6 million in a Series A round led by Iberis Capital to expand its regulated remote patient monitoring platform across Europe, adding new offices in Germany and Romania and scaling programmes in Portugal, France and Switzerland.
The BioInnovation Institute (BII) announced an additional €7.8 million grant, split as €1.3 million per company, for six Danish spin‑outs working on antibody cancer therapies, AI‑powered ultrasound, inflammatory disease treatments, biological pest control, vaccine‑based immunotherapies, and waste‑to‑fuel technology. The funding builds on a prior €500 k grant each, bringing total support to €1.8 million per company and includes continued access to BII’s Copenhagen innovation platform.
Soulhouse, a European wellness startup, secured €20 million to accelerate its product development and market expansion.